Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2

References

• Clinical Practice Guideline for the Diagnosis and Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD) – Spanish Guideline for COPD (GesEPOC). Task Force of GesEPOC. Arch Bronconeumol. 2017;53(Supl1):2–64.
   Google Scholar
• AlmagroP, LópezF, CabreraFJ, et al. Soriano JB y Grupos de trabajo de EPOC y Paciente Pluripatológico y Edad Avanzada de la Sociedad Española de Medicina Interna. Comorbidities in patients hospitalized due to chronic obstructive pulmonary disease. A comparative analysis of the ECCO and ESMI studies. Rev Clin Esp. 2012;212(6):281. doi:10.1016/j.rce.2012.02.01422521437
   PubMed Web of Science ®Google Scholar
• EmamiA, JavanmardiF, PirbonyehN, AkbariA. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e35.32232218
   PubMedGoogle Scholar
• GuanWJ, LiangWH, ZhaoY, et al.; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020.32217650
   PubMed Web of Science ®Google Scholar
• LeungJM, YangCX, TamA, et al. ACE-2 expression in the small Airway Epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55:2000688. doi:10.1183/13993003.00688-202032269089
   PubMed Web of Science ®Google Scholar
• ZieglerCGK, AllonSJ, NyquistSK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human Airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016–1035. doi:10.1016/j.cell.2020.04.03532413319
   PubMed Web of Science ®Google Scholar
• RadzikowskaU, DingM, TanG, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75(11):2829–2845. doi:10.1111/all.1442932496587
   PubMed Web of Science ®Google Scholar
• ImaiY, KubaK, RaoS, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–116. doi:10.1038/nature0371216001071
   PubMed Web of Science ®Google Scholar
• ZhaoQ, MengM, KumarR, et al. The impact of COPD and smoking history on the severity of Covid-19: a systemic review and meta-analysis. J Med Virol. 2020. doi:10.1002/jmv.25889
   Web of Science ®Google Scholar
• AlqahtaniJS, OyeladeT, AldhahirAM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15(5). doi:10.1371/journal.pone.0233147
   Web of Science ®Google Scholar
• San Román TeránCM, Guijarro MerinoM, Gómez HuelgasR, Montero RibasL. Hospital Epidemiology of COPD in Spain. Rev Clin Esp. 2007;207(Supl 1):3–7.
   Google Scholar
• Casas RojoJM, Antón SantosJM, Millán Núñez-CortésJ, et al.; for the SEMI-COVID-19 Network. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMICOVID-19 network. Rev Clin Esp. 2020. doi:10.1016/j.rce.2020.07.003
   Web of Science ®Google Scholar
• XuG, YangY, DuY, et al. Clinical pathway for early diagnosis of COVID-19: updates from experience to evidence-based practice. Clin Rev Allergy Immunol. 2020;24:1–12.
   Google Scholar
• BoixedaR, CampinsL, JuanolaJ, ForceL. Is chronic obstructive pulmonary disease a protective factor in SARS-CoV-2 infection? The importance of bronchodilator treatment. Rev Clin Esp. 2020;220(8):526–528. doi:10.1016/j.rce.2020.07.00132836322
   PubMed Web of Science ®Google Scholar
• YamayaM, NishimuraH, DengX, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58:155–168. doi:10.1016/j.resinv.2019.12.005
   PubMed Web of Science ®Google Scholar
• AlmagroP, CabreraFJ, Diez-ManglanoJ, et al.; Working Group on COPD, Spanish Society of Internal Medicine. Comorbidome and short-term prognosis in hospitalised COPD patients: the ESMI study. Eur Respir J. 2015;46:850–853. doi:10.1183/09031936.00008015.25900375
   PubMed Web of Science ®Google Scholar
• RobertsCM, StoneRA, LoweD, PurseyNA, BuckinghamRJ. Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD. 2011;8:354–361. doi:10.3109/15412555.2011.60036221864116
   PubMedGoogle Scholar
• AlqahtaniJS, NjokuCM, BereznickiB, et al. Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. Eur Respir Rev. 2020;29:190166. doi:10.1183/16000617.0166-201932499306
   PubMed Web of Science ®Google Scholar
• SeiduS, GilliesC, ZaccardiF, et al. The impact of obesity on severe disease and mortality in people with SARS-CoV-2: a systematic review and meta-analysis. Endocrinol Diabetes Metab. 2020;14:e00176. doi:10.1002/edm2.176
   Google Scholar
• SpeltaF, Fratta PasiniAM, CazzolettiL, FerrariM. Body weight and mortality in COPD: focus on the obesity paradox. Eat Weight Disord. 2018;23:15–22. doi:10.1007/s40519-017-0456-z29110280
   PubMed Web of Science ®Google Scholar
• SokolowskaM, LukasikZ, AgacheI, et al. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics and perspectives - a report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020;75(10):2445–2476. doi:10.1111/all.1446232584441
   PubMed Web of Science ®Google Scholar
• KoFW, IpM, ChanPKS, et al. Viral Etiology of Acute Exacerbations of COPD in Hong Kong. Chest. 2007;132:900–908. doi:10.1378/chest.07-053017573516
   PubMed Web of Science ®Google Scholar
• KuraiD, SarayaT, IshiiH, TakizawaH. Virus-induced exacerbations in asthma and COPD. Front Microbiol. 2013;4:293.24098299
   PubMed Web of Science ®Google Scholar
• GuanWJ, NiZY, HuY, et al.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382;2020:1708–1720. doi:10.1056/NEJMoa200203232109013
   PubMed Web of Science ®Google Scholar
• WangB, LivR, LuZ, HuangY. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12:6049–6057. doi:10.18632/aging.10300032267833
   PubMedGoogle Scholar
• WangL, HeW, YuX, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020;80:639–645. doi:10.1016/j.jinf.2020.03.01932240670
   PubMed Web of Science ®Google Scholar
• ParohanM, YaghoubiS, SerajiA, JavanbakhtMH, SarrafP, DjalaliM. Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020;8:1–9. doi:10.1080/13685538.2020.1774748
   Web of Science ®Google Scholar
• LippiG. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941.32421537
   PubMed Web of Science ®Google Scholar
• CenY, ChenX, ShenY, et al. Risk factors for disease progression in mild to moderate COVID-19 patients- a multi-center observational study. Clin Microbiol Infect. 2020;S1198-743X(20)30341–4.
   PubMed Web of Science ®Google Scholar
• LippiG, HenryBM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107–108. doi:10.1016/j.ejim.2020.03.01432192856
   PubMed Web of Science ®Google Scholar
• GuoFR. Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): an update of a meta-analysis. Tob Induc Dis. 2020;18:37. doi:10.18332/tid/12191532382258
   PubMed Web of Science ®Google Scholar
• LippiG, Sanchis-GomarF, HenryBM. Active smoking and COVID-19: a double-edged sword. Eur J Intern Med. 2020;S0953-6205(20)30182–5.
   Web of Science ®Google Scholar
• FarsalinosK, BarbouniA, PoulasK, PolosaR, CaponnettoP, NiauraR. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2020;11:2040622320935765. doi:10.1177/204062232093576532637059
   PubMed Web of Science ®Google Scholar
• VardavasCI, NikitaraK. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18:20. doi:10.18332/tid/11932432206052
   PubMed Web of Science ®Google Scholar
• CelliBR. Predictors of Mortality in COPD. Respir Med. 2010;104:773–779. doi:10.1016/j.rmed.2009.12.01720417082
   PubMed Web of Science ®Google Scholar
• AlmagroP, SorianoJB, CabreraFJ, et al.; Working Group on COPD, SpanishSociety of Internal Medicine*. Short and medium term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014;145(5):972–980. doi:10.1378/chest.13-132824077342
   PubMed Web of Science ®Google Scholar
• AttawayA. Management of patients with COPD during the COVID-19 pandemic. Cleve Clin J Med. 2020. doi:10.3949/ccjm.87a.ccc007
   PubMed Web of Science ®Google Scholar
• BhutaniM, HernandezP, BourbeauJ, et al. KEY HIGHLIGHTS of the Canadian Thoracic Society’s position statement on the optimization of chronic obstructive pulmonary disease management during the COVID-19 pandemic. Chest. 2020;S0012-3692(20)31456–2.
   Web of Science ®Google Scholar
• CaoB, WangY, WenD, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382:1787–1799. doi:10.1056/NEJMoa200128232187464
   PubMed Web of Science ®Google Scholar
• GautretP, LagierJC, ParolaP, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi:10.1016/j.ijantimicag.2020.10594932205204
   PubMed Web of Science ®Google Scholar
• DevauxCA, RolainJM, ColsonP, RaoultD. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938. doi:10.1016/j.ijantimicag.2020.10593832171740
   PubMed Web of Science ®Google Scholar
• TripathyS, DassarmaB, RoyS, ChabalalaH, MatsabisaMG. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents. 2020;56:106028. doi:10.1016/j.ijantimicag.2020.10602832450198
   PubMed Web of Science ®Google Scholar
• McGonagleD, SharifK, O’ReganA, et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19:102537. doi:10.1016/j.autrev.2020.10253732251717
   PubMed Web of Science ®Google Scholar
• XuX, HanM, LiT, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975. doi:10.1073/pnas.200561511732350134
   PubMed Web of Science ®Google Scholar
• ToniatiP, PivaS, CattaliniM, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi:10.1016/j.autrev.2020.10256832376398
   PubMed Web of Science ®Google Scholar
• CavalliG, De LucaG, CampochiaroC, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331. doi:10.1016/S2665-9913(20)30127-232501454
   PubMedGoogle Scholar
• LipworthB, ChanR, LipworthS, RuiC, KuoW. Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. J Allergy Clin Immunol Pract. 2020;8(6):1798–1801. doi:10.1016/j.jaip.2020.04.01432311489
   PubMed Web of Science ®Google Scholar